poisar

Stocks · News reference

CRISPR Therapeutics to Present Clinical Data for Zugo-cel at 68th ASH Annual Meeting

Fiscal.ai

CRISPR Therapeutics announced that clinical data from its Phase 1/2 trial of zugocabtagene geleucel (zugo-cel) in relapsed or refractory large B-cell lymphoma will be presented at the upcoming ASH Annual Meeting.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolBrendan Coffey

    Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

    The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.